Cargando…
Reversion of in vivo fibrogenesis by novel chromone scaffolds
BACKGROUND: Myofibroblasts are known to play a key role in the development of idiopathic pulmonary fibrosis (IPF). Two drugs, pirfenidone and nintedanib, are the only approved therapeutic options for IPF, but their applications are limited due to their side effects. Thus, curative IPF drugs represen...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355727/ https://www.ncbi.nlm.nih.gov/pubmed/30611717 http://dx.doi.org/10.1016/j.ebiom.2018.12.017 |
_version_ | 1783391372219252736 |
---|---|
author | Kim, Han-Soo Yoon, Young-Min Meang, Moon Kee Park, Yae Eun Lee, Ji Yong Lee, Tae Hee Lee, Ji Eun Kim, Ik-Hwan Youn, Byung-Soo |
author_facet | Kim, Han-Soo Yoon, Young-Min Meang, Moon Kee Park, Yae Eun Lee, Ji Yong Lee, Tae Hee Lee, Ji Eun Kim, Ik-Hwan Youn, Byung-Soo |
author_sort | Kim, Han-Soo |
collection | PubMed |
description | BACKGROUND: Myofibroblasts are known to play a key role in the development of idiopathic pulmonary fibrosis (IPF). Two drugs, pirfenidone and nintedanib, are the only approved therapeutic options for IPF, but their applications are limited due to their side effects. Thus, curative IPF drugs represent a huge unmet medical need. METHODS: A mouse hepatic stellate cell (HSC) line was established that could robustly differentiate into myofibroblasts upon treatment with TGF-β. Eupatilin was assessed in diseased human lung fibroblasts from IPF patients (DHLFs) as well as in human lung epithelial cells (HLECs). The drug's performance was extensively tested in a bleomycin-induced lung fibrosis model (BLM). Global gene expression studies and proteome analysis were performed. FINDINGS: Eupatilin attenuated disease severity of BLM in both preventative and therapeutic studies. The drug inhibited the in vitro transdifferantiation of DHLFs to myofibroblasts upon stimulation with TGF-β. No such induction of the in vitro transdifferantiation was observed in TGF-β treated HLECs. Specific carbons of eupatilin were essential for its anti-fibrotic activity. Eupatilin was capable of dismantling latent TGF-β complex, specifically by eliminating expression of the latent TGF-β binding protein 1 (LTBP1), in ECM upon actin depolymerization. Unlike eupatilin, pirfenidone was unable to block fibrosis of DHLFs or HSCs stimulated with TGF-β. Eupatilin attenuated phosphorylation of Smad3 by TGF-β. Eupatilin induced myofibroblasts to dedifferentiate into intermediate HCS-like cells. INTERPRETATION: Eupatilin may act directly on pathogenic myofibroblasts, disarming them, whereas the anti-fibrotic effect of pirfenidone may be indirect. Eupatilin could increase the efficacy of IPF treatment to curative levels. |
format | Online Article Text |
id | pubmed-6355727 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-63557272019-02-08 Reversion of in vivo fibrogenesis by novel chromone scaffolds Kim, Han-Soo Yoon, Young-Min Meang, Moon Kee Park, Yae Eun Lee, Ji Yong Lee, Tae Hee Lee, Ji Eun Kim, Ik-Hwan Youn, Byung-Soo EBioMedicine Research paper BACKGROUND: Myofibroblasts are known to play a key role in the development of idiopathic pulmonary fibrosis (IPF). Two drugs, pirfenidone and nintedanib, are the only approved therapeutic options for IPF, but their applications are limited due to their side effects. Thus, curative IPF drugs represent a huge unmet medical need. METHODS: A mouse hepatic stellate cell (HSC) line was established that could robustly differentiate into myofibroblasts upon treatment with TGF-β. Eupatilin was assessed in diseased human lung fibroblasts from IPF patients (DHLFs) as well as in human lung epithelial cells (HLECs). The drug's performance was extensively tested in a bleomycin-induced lung fibrosis model (BLM). Global gene expression studies and proteome analysis were performed. FINDINGS: Eupatilin attenuated disease severity of BLM in both preventative and therapeutic studies. The drug inhibited the in vitro transdifferantiation of DHLFs to myofibroblasts upon stimulation with TGF-β. No such induction of the in vitro transdifferantiation was observed in TGF-β treated HLECs. Specific carbons of eupatilin were essential for its anti-fibrotic activity. Eupatilin was capable of dismantling latent TGF-β complex, specifically by eliminating expression of the latent TGF-β binding protein 1 (LTBP1), in ECM upon actin depolymerization. Unlike eupatilin, pirfenidone was unable to block fibrosis of DHLFs or HSCs stimulated with TGF-β. Eupatilin attenuated phosphorylation of Smad3 by TGF-β. Eupatilin induced myofibroblasts to dedifferentiate into intermediate HCS-like cells. INTERPRETATION: Eupatilin may act directly on pathogenic myofibroblasts, disarming them, whereas the anti-fibrotic effect of pirfenidone may be indirect. Eupatilin could increase the efficacy of IPF treatment to curative levels. Elsevier 2019-01-02 /pmc/articles/PMC6355727/ /pubmed/30611717 http://dx.doi.org/10.1016/j.ebiom.2018.12.017 Text en © 2018 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Research paper Kim, Han-Soo Yoon, Young-Min Meang, Moon Kee Park, Yae Eun Lee, Ji Yong Lee, Tae Hee Lee, Ji Eun Kim, Ik-Hwan Youn, Byung-Soo Reversion of in vivo fibrogenesis by novel chromone scaffolds |
title | Reversion of in vivo fibrogenesis by novel chromone scaffolds |
title_full | Reversion of in vivo fibrogenesis by novel chromone scaffolds |
title_fullStr | Reversion of in vivo fibrogenesis by novel chromone scaffolds |
title_full_unstemmed | Reversion of in vivo fibrogenesis by novel chromone scaffolds |
title_short | Reversion of in vivo fibrogenesis by novel chromone scaffolds |
title_sort | reversion of in vivo fibrogenesis by novel chromone scaffolds |
topic | Research paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6355727/ https://www.ncbi.nlm.nih.gov/pubmed/30611717 http://dx.doi.org/10.1016/j.ebiom.2018.12.017 |
work_keys_str_mv | AT kimhansoo reversionofinvivofibrogenesisbynovelchromonescaffolds AT yoonyoungmin reversionofinvivofibrogenesisbynovelchromonescaffolds AT meangmoonkee reversionofinvivofibrogenesisbynovelchromonescaffolds AT parkyaeeun reversionofinvivofibrogenesisbynovelchromonescaffolds AT leejiyong reversionofinvivofibrogenesisbynovelchromonescaffolds AT leetaehee reversionofinvivofibrogenesisbynovelchromonescaffolds AT leejieun reversionofinvivofibrogenesisbynovelchromonescaffolds AT kimikhwan reversionofinvivofibrogenesisbynovelchromonescaffolds AT younbyungsoo reversionofinvivofibrogenesisbynovelchromonescaffolds |